All updates
All updates
today 47文献与产业新闻评分4747 中文产业新闻Chinese source评分6464 阿斯利康/安进特泽利尤单抗嗜酸性食管炎3期CROSSING试验达共同主要终点
中文产业新闻Chinese source评分6666 恒瑞HRS-7535糖尿病肾病Ⅱ期SOLID-DKD研究在《eClinicalMedicine》发表
中文产业新闻Chinese source评分6565 Moderna 个体化新抗原 mRNA 疫苗为何率先跑通 Ⅲ期
中文产业新闻精选Chinese source评分7272 Moderna mRNA-4157 个性化新抗原疫苗 III 期联合帕博利珠单抗显著改善黑色素瘤 RFS 与 DMFS
中文产业新闻Chinese source评分6666 阿斯利康与安进联合开发的Tezspire在EoE 3期CROSSING试验中达到双主要终点
顶刊论文（社媒热度）精选评分6161 Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
文献与产业新闻精选评分5757 STAT+: Cytokinetics details trial win for what could be its next approval
顶刊论文（社媒热度）精选评分5959 Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%: The CMR GUIDE Randomized Clinical Trial.
顶刊论文（社媒热度）精选评分6060 Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
NEJM评分00 Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
顶刊论文（社媒热度）精选评分5757 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis.
NEJM评分00 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
顶刊论文（社媒热度）精选评分7070 Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.
NEJM评分00 Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
The Lancet评分4242 [Articles] Physiotherapist-led care for musculoskeletal conditions in the emergency department (RESHAP-ED): a randomised controlled trial with economic evaluation
The Lancet评分3232 [Clinical Rounds] Generalised eruptive histiocytosis mimicking lymphoma relapse in a patient with previous diffuse large B-cell lymphoma
顶刊论文（社媒热度）评分4242 Azithromycin for Preschoolers with Wheezing in the Emergency Department.
文献与产业新闻评分5050 ESC: Cytokinetics delves deeper on ‘huge’ Myqorzo readout, fueling cardiomyopathy expansion bid
中文产业新闻Chinese source评分6565 阿斯利康与安进TEZSPIRE治疗嗜酸性粒细胞性食管炎3期CROSSING试验达主要终点
中文产业新闻Chinese source评分6262 阿斯利康Tezspire治疗嗜酸性粒细胞性食管炎III期CROSSING研究取得高水平阳性结果
文献与产业新闻评分4343 Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent
顶刊论文（社媒热度）评分5050 CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.
文献与产业新闻评分4747 CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial
顶刊论文（社媒热度）精选评分6969 Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.
顶刊论文（社媒热度）评分4646 Carbocisteine or Hypertonic Saline for Acute Respiratory Failure.
文献与产业新闻评分1515 STAT+: Key data on a new class of cardio drugs are coming
中文产业新闻Chinese source评分6060 石药SYS6010首个III期研究SYNSTAR-01达到PFS主要终点
中文产业新闻Chinese source评分6767 石药集团巨石生物 EGFR ADC SYS6010 在 III 期 SYNSTAR-01 试验中达到 PFS 主要终点
中文产业新闻精选Chinese source评分8282 康方依沃西HARMONi-GI1三期达到OS主要终点，对照度伐利尤单抗联合化疗
中文产业新闻精选Chinese source评分6868 康方依沃西胆道癌III期头对头试验达主要终点
文献与产业新闻评分3535 Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
文献与产业新闻评分2020 Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
文献与产业新闻评分4343 Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
文献与产业新闻评分3939 A multi-faceted hospital-based intervention for intrapartum care in sub-Saharan Africa: a stepped-wedge cluster-randomized trial
文献与产业新闻评分3636 Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial
顶刊论文（社媒热度）精选评分5555 Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
中文产业新闻精选Chinese source评分7272 中美华世通WS016高钾血症Ⅲ期试验达到主要终点
中文产业新闻精选Chinese source评分7070 阿斯利康 Volrustomig 一线 NSCLC 三期 eVOLVE-Lung02 因何落败
中文产业新闻Chinese source评分6767 Moderna个性化mRNA肿瘤疫苗intismeran联合KEYTRUDA在III期INTerpath-001试验取得阳性结果